Supernus Pharmaceuticals, Inc.
SUPN· Nasdaq
SUPNSupernus Pharmaceuticals, Inc.
Source filing unavailable
| Metric | Q1 2013 | Q1 2012 | Q1 2011 |
|---|---|---|---|
| Revenue | $147.00K | $208.00K | — |
| Net Income | -$18.41M | -$9.28M | -$11.05M |
| EPS Diluted | -$0.60 | -$6.05 | -$6.64 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
